-
Extended interval dosing with ocrelizumab in multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-22 Frederik Novak, Hamza Mahmood Bajwa, Kamilla Østergaard, Jonas Munksgaard Berg, Jonna Skov Madsen, Dorte Aalund Olsen, Inga Urbonaviciute, Zsolt Illes, Morten Leif Stilund, Jeppe Romme Christensen, Stephan Bramow, Finn Sellebjerg, Tobias Sejbaek
Background:This study investigates clinical and biomarker differences between standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple sclerosis (MS).Methods:This is a prospective, double-arm, open-label, multi-center study in Denmark. Participants diagnosed with MS on ocrelizumab therapy >12 months were included ( n = 184). Clinical, radiological, and blood-based
-
Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein–associated disease Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-22 Alessia Bianchi, Rosa Cortese, Ferran Prados, Carmen Tur, Baris Kanber, Marios C Yiannakas, Rebecca Samson, Floriana De Angelis, Lise Magnollay, Anu Jacob, Wallace Brownlee, Anand Trip, Richard Nicholas, Yael Hacohen, Frederik Barkhof, Olga Ciccarelli, Ahmed T Toosy
Background:Optic neuritis (ON) is a common feature of inflammatory demyelinating diseases (IDDs) such as multiple sclerosis (MS), aquaporin 4-antibody neuromyelitis optica spectrum disorder (AQP4 + NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD). However, the involvement of the optic chiasm (OC) in IDD has not been fully investigated.Aims:To examine OC differences
-
Multiple sclerosis can be diagnosed solely with dissemination in space: Commentary Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-15 Marisa P McGinley, Jeffrey A Cohen
-
Therapeutic lag: Is treatment effect delayed in progressive MS? Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-15 Noemi Montobbio, Francesca Bovis, Alessio Signori, Marta Ponzano, Irene Schiavetti, Maria Pia Sormani
Background:Randomized clinical trials (RCTs) in progressive multiple sclerosis (MS) often revealed non-significant treatment effects on disability progression.Objectives:To investigate whether the failure to detect a significant benefit from treatment may be motivated by a delay in treatment effect, possibly related to baseline characteristics.Methods:We re-analyzed data from two RCTs testing interferon-beta
-
Multiple sclerosis can be diagnosed solely with dissemination in space: Yes Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-15 Ahmed T Toosy, Frederik Barkhof
-
Multiple sclerosis can be diagnosed solely with dissemination in space: No Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-15 Christopher C Hemond, Andrew J Solomon
-
Prevalence and incidence of multiple sclerosis in Turkey: A nationwide epidemiologic study Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-15 Bilgin Öztürk, Esra Taşkıran, Serkan Demir, Meryem Aslı Tuncer, Murat Kürtüncü, Rana Karabudak, Aksel Siva, Hüsnü Efendi, Naim Ata, Mustafa Mahir Ülgü, Şuayip Birinci
Background:Many studies on multiple sclerosis (MS) reveal different prevalence and epidemiologic results.Objectives:In this study, we aimed to determine the epidemiologic profile of MS using official health records in Turkey.Methods:Patients diagnosed with MS from the official health data of the Ministry of Health, representing the entire population of Turkey, were included in the study. Prevalence
-
Radiologically isolated syndrome in the spectrum of multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-15 Darin T Okuda, Christine Lebrun-Frénay
The radiologically isolated syndrome (RIS) currently represents the earliest detectable preclinical phase of multiple sclerosis (MS). Remarkable advancements have been recently made, including the identification of risk factors for disease evolution, revisions to the existing 2009 RIS criteria, and our understanding of the impact of early disease-modifying therapy use in the prevention/delay of symptomatic
-
Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-15 Tanuja Chitnis, Brenda Banwell, Ludwig Kappos, Douglas L Arnold, Kivilcim Gücüyener, Kumaran Deiva, Stephane Saubadu, Wenruo Hu, Myriam Benamor, Annaig Le-Halpere, Philippe Truffinet, Marc Tardieu
Background:The double-blind TERIKIDS study demonstrated the efficacy and safety of teriflunomide.Objective:To evaluate the efficacy, safety, and tolerability of continuous teriflunomide treatment in the TERIKIDS open-label extension.Methods:In the double-blind period, children with relapsing MS were randomized to placebo or teriflunomide (14 mg adult-equivalent dose) for ⩽ 96 weeks. Participants received
-
New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-12 Megan Schneider, John Kramer, Aimee Banks, Harold Moses
Lymphopenia is a known adverse effect in patients with relapsing multiple sclerosis (RMS) treated with fumaric acids. We present a case series of four patients diagnosed with RMS with prolonged lymphocyte stability on dimethyl fumarate for over 1 year who developed significant lymphopenia after transitioning to diroximel fumarate. This case series highlights the need for further research to elucidate
-
Drug-induced lymphopenia: Are all fumarates the same? Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-12 Ralf Gold, Jeremias Motte
-
Neurofilament in clinical practice: Is the multiple sclerosis community ready? Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-12 Marcello Moccia, Daniela Terracciano, Vincenzo Brescia Morra, Giuseppe Castaldo
-
EBV infection drives MS pathology: Yes Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-11 Francesca Aloisi, Marco Salvetti
-
EBV infection drives MS pathology: Commentary Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-11 Marianna Cortese, Alberto Ascherio
-
EBV infection drives MS pathology: No Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-11 Bert A ‘t Hart, Marvin M van Luijn
-
Risk of depression and anxiety in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea Mult. Scler. J. (IF 5.8) Pub Date : 2024-04-02 Soonwook Kwon, Kyung-Do Han, Jin Hyung Jung, Eun Bin Cho, Yeon Hak Chung, Junhee Park, Hea Lim Choi, Hong Jin Jeon, Dong Wook Shin, Ju-Hong Min
Background:We investigated the risks of depression/anxiety in patients with multiple sclerosis (pwMS) or patients with neuromyelitis optica spectrum disorder (pwNMOSD).Objectives:MS/NMOSD cohorts were collected from Korean National Health Insurance Service, using the International Classification of Diseases-10th and information on Rare Intractable Disease program. Patients who were younger than 20
-
Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-29 Agustin Pappolla, Cristina Auger, Augusto Sao-Aviles, Carmen Tur, Marta Rodriguez-Barranco, Álvaro Cobo-Calvo, Neus Mongay-Ochoa, Breogán Rodríguez-Acevedo, Ana Zabalza, Luciana Midaglia, Pere Carbonell-Mirabent, Rene Carvajal, Joaquín Castilló-Justribó, Nathane Braga, Luca Bollo, Angela Vidal-Jordana, Georgina Arrambide, Carlos Nos, Annalaura Salerno, Ingrid Galán, Manuel Comabella, Jaume Sastre-Garriga
Background:Limited data exist regarding treatment response prediction to oral disease-modifying therapies (DMTs) in multiple sclerosis (MS).Objectives:We assessed the capacity of available scoring systems to anticipate disease activity parameters in naïve relapsing–remitting MS (RRMS) patients initiating daily oral DMTs, hypothesizing that they exhibit different predictive potentials.Methods:We conducted
-
Autologous hematopoietic stem cells transplantation in MOGAD Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-25 Sara Mariotto, Sara Carta
-
Torben Fog – A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-25 Per Soelberg Sørensen, Stephan Bramow, Melinda Magyari, Lene Werdelin, Nils Koch-Henriksen, Patrick Vermersch, Finn Sellebjerg
Torben Fog was committed to multiple sclerosis (MS) research for more than four decades, starting before the defence of his thesis in 1948 and lasting until his death in 1987. His research was multi-facetted, making him one of the great pioneers in the study of essential parts of the pathology, immunology and treatment of MS. He has contributed with meticulous studies of the MS plaques, documenting
-
Structural MRI measures are associated with fatigue severity and persistence in a large, real-world cohort of people with multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-25 Alexandra C Simpson, Chen Hu, Ellen M Mowry, Robert T Naismith, Kathryn C Fitzgerald, Bardia Nourbakhsh
Background:Results of research on radiological hallmarks of multiple sclerosis (MS) fatigue have been conflicting.Objective:To investigate the associations of lesion and brain compartment volumes with fatigue severity and persistence in people with multiple sclerosis (PwMS).Methods:The Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) network collects standardized data
-
Clinical correlates of respiratory disorders in patients with severe multiple sclerosis: A cross-sectional cohort Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-23 Elisabeth Maillart, Stefania Redolfi, Céline Louapre, Marion Houot, Emeline Chaugne, Pierantonio Laveneziana, Aurelian Ungureanu, Bruno Stankoff, Isabelle Arnulf, Caroline Papeix, Benedetta Bodini, Thomas Similowski, Catherine Lubetzki, Capucine Morélot-Panzini
Background:Respiratory disorders remain incompletely described in multiple sclerosis (MS), even though they are a frequent cause of death.Methods:The objective was to describe respiratory disorders in MS patients with Expanded Disability Status Score (EDSS) ⩾ 6.5. Diaphragm dysfunction was defined by at least two of the seven criteria: clinical signs, inspiratory recruitment of neck muscles during
-
Infectious mononucleosis and risk of multiple sclerosis: Proxy or culprit? Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-21 Henrik Hjalgrim, Klaus Rostgaard
-
No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-21 Maria Pia Campagna, Eva Kubala Havrdova, Dana Horakova, Guillermo Izquierdo, Fuencisla Matesanz, Sara Eichau, Jeannette Lechner-Scott, Bruce V Taylor, Maria-Isabel García-Sanchéz, Antonio Alcina, Anneke van der Walt, Helmut Butzkueven, Vilija G Jokubaitis
Background:The International Multiple Sclerosis Genetics Consortium and MultipleMS Consortium recently reported a genetic variant associated with multiple sclerosis (MS) severity. However, it remains unclear if these variants remain associated with more robust, longitudinal measures of disease severity.Methods:We examined the top variant, rs10191329, from Harroud et al.’s study in 1813 relapse-onset
-
Risk of multiple sclerosis in individuals with infectious mononucleosis: a national population-based cohort study using hospital records in England, 2003–2023 Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-21 Raphael Goldacre
Background:Epstein–Barr virus (EBV) is thought to be a necessary causative agent in the development of multiple sclerosis (MS). Infectious mononucleosis (IM), which occurs up to 70% of adolescents and young adults with primary EBV infection, appears to be a further risk factor but few studies have been highly powered enough to explore this association by time since IM diagnosis.Objective:The objective
-
Facial pain in MS: When to think of trigeminal autonomic cephalalgia Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-21 Sanjay Cheema, Manjit Matharu
-
Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-14 M Johnsson, YT Stenberg, HH Farman, K Blennow, H Zetterberg, C Malmeström, S Sandgren, I Rosenstein, J Lycke, M Axelsson, L Novakova
Background:Serum neurofilament light (sNfL) reflects neuroaxonal damage and is now used as an outcome in treatment trials of relapsing-remitting multiple sclerosis (RRMS). However, the diagnostic properties of sNfL for monitoring disease activity in individual patients warrant further investigations.Method:Patients with suspected relapse and/or contrast-enhancing lesions (CELs) were consecutively included
-
Choroid plexus volume differentiates MS from its mimics Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-14 Elle Levit, Zheng Ren, Virgilio Gonzenbach, Christina J Azevedo, Peter A Calabresi, Bruce AC Cree, Leorah Freeman, Erin E Longbrake, Jiwon Oh, Matthew K Schindler, Nancy L Sicotte, Daniel S Reich, Daniel Ontaneda, Pascal Sati, Quy Cao, Russell T Shinohara, Andrew J Solomon
This study aimed to determine whether choroid plexus volume (CPV) could differentiate multiple sclerosis (MS) from its mimics. A secondary analysis of two previously enrolled studies, 50 participants with MS and 64 with alternative diagnoses were included. CPV was automatically segmented from 3T magnetic resonance imaging (MRI), followed by manual review to remove misclassified tissue. Mean normalized
-
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-14 Fabrizia Mealli, Alessandra Mattei, Alice Mariottini, Luca Massacesi
To quantify the probability that monthly intravenous (IV) and subcutaneous (SC) natalizumab (NTZ) had similar efficacy in relapsing-remitting multiple sclerosis (RRMS), non-inferiority of efficacy of NTZ-SC versus NTZ-IV on combined MRI unique active lesions number (CUAL) was explored re-analysing the REFINE data set. Non-inferiority margins were selected equal to 25%/33%/50% fractions of the effect
-
Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-12 Kunio Nakamura, Zhaonan Sun, Claire Hara-Cleaver, Karthik Bodhinathan, Robin L Avila
Background:Loss of brain gray matter fractional volume predicts multiple sclerosis (MS) progression and is associated with worsening physical and cognitive symptoms. Within deep gray matter, thalamic damage is evident in early stages of MS and correlates with physical and cognitive impairment. Natalizumab is a highly effective treatment that reduces disease progression and the number of inflammatory
-
Letter to the editor: Mobile health interventions in multiple sclerosis: A systematic review Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-11 Rainer Ehling, Barbara Seebacher, Christian Brenneis
-
Iatrogenic myelodysplastic syndrome complicating multiple sclerosis: A case report Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-09 Konrad Kubicki, Dusan Stefoski
After 1.5 years of treatment with dimethyl fumarate (DMF) for multiple sclerosis, preceded 8 years earlier by intravenous (IV) cladribine and 1 year earlier by natalizumab, our patient developed myelodysplastic syndrome (MDS). The initial manifestation was a severe drop in absolute neutrophil and lymphocyte counts. Repeat bone marrow biopsy demonstrated a new unbalanced translocation (between the chromosome
-
Expert opinion on the use of contraception in people with multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-08 Jan Hillert, Riley Bove, Lisa B Haddad, Kerstin Hellwig, Maria Houtchens, Melinda Magyari, Gabriele S Merki-Feld, Scott Montgomery, Rossella E Nappi, Egon Stenager, Heidi Thompson, Zeliha Tulek, Elisabetta Verdun Di Cantogno, Manuela Simoni
Background:Current guidance on the selection of appropriate contraception for people with multiple sclerosis (PwMS) is lacking.Objective:To address this gap, an expert-led consensus program developed recommendations to support clinicians in discussing family planning and contraception with women and men with multiple sclerosis (MS).Methods:A multidisciplinary steering committee (SC) of 13 international
-
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-08 Maria Grazia Aprea, Irene Schiavetti, Emilio Portaccio, Chiara Ballerini, Simona Bonavita, Maria Buscarinu, Massimiliano Calabrese, Paola Cavalla, Maria Cellerino, Cinzia Cordioli, Vincenzo Dattola, Stefano De Biase, Ermelinda De Meo, Roberta Fantozzi, Antonio Gallo, Luigi Iasevoli, Rana Karabudak, Doriana Landi, Lorena Lorefice, Lucia Moiola, Paolo Ragonese, Francesca Ruscica, Sedat Sen, Leonardo
Background:In the general population, maternal COVID-19 is associated with worse maternal and fetal outcomes. Two previous studies have assessed COVID-19 clinical outcomes in pregnant women with multiple sclerosis (MS), but there are no data about maternal and fetal outcomes.Objectives:In this multicenter study, we aimed to assess maternal and fetal outcomes in pregnant women with MS and COVID-19 infection
-
Tick-borne illnesses in patients treated with B-cell depleting agents: Considerations for neurologists Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-07 Hamza Coban
-
Aspergillus myelitis: Breaking the mold to make a diagnosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-07 Eoin P Flanagan
-
Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-04 Xavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, Pascal Benkert, Douglas L Arnold, Martin S Weber, Andrea Seitzinger, Hans Guehring, Jamie Shaw, Davorka Tomic, Yann Hyvert, Danielle E Harlow, Martin Dyroff, Jerry S Wolinsky
Background:Evobrutinib – an oral, central nervous system (CNS)-penetrant, and highly selective Bruton’s tyrosine kinase inhibitor – has shown efficacy in a 48-week, double-blind, Phase II trial in patients with relapsing MS.Objective:Report results of the Phase II open-label extension (OLE; up to week 192 from randomisation) and a cerebrospinal fluid (CSF) sub-study.Methods:In the 48-week double-blind
-
Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-01 Christopher E McMurran, Trisha Mukherjee, J William L Brown, Alasdair J Coles, Nick G Cunniffe
The Cambridge Centre for Myelin Repair One (CCMR-One) trial showed that 6 months of bexarotene reduces visual evoked potential (VEP) latency in people with relapsing-remitting multiple sclerosis (MS). In a single-centre follow-up study of these participants, we re-examined full-field VEP and clinical assessments. Twenty participants (12 bexarotene and 8 placebo) were seen on average 27 months after
-
Increased levels of circulating soluble CD226 in multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-01 Saniya Kari, Florence Bucciarelli, Thibault Angles, Anne-Cecile Oster, Pauline Cauboue, Karl Laviolette, Madeline Mougenot, Elena Morandi, Isabelle Bernard, Beatrice Pignolet, Chloé Bost, Joelle Thomas, Leonor Nogueira, Abdelhadi Saoudi, Roland Liblau, Anne L Astier
Background:The glycoprotein CD226 plays a key role in regulating immune cell function. Soluble CD226 (sCD226) is increased in sera of patients with several chronic inflammatory diseases but its levels in neuroinflammatory diseases such as multiple sclerosis (MS) are unknown.Objective:To investigate the presence and functional implications of sCD226 in persons with multiple sclerosis (pwMS) and other
-
SUNCT syndrome secondary to multiple sclerosis: Not only trigeminal neuralgia Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-01 Giada Giuliani, Chiara Zilli, Francesca Caramia, Vittorio Di Piero, Marta Altieri
Background:Facial pain in multiple sclerosis is often due to trigeminal neuralgia but atypical pictures can be observed.Case presentation:A man with primary progressive multiple sclerosis developed severe unilateral facial pain in the right orbital region. Spontaneous and triggered attacks were associated with ipsilateral conjunctival injection and lacrimation. A diagnosis of short-lasting unilateral
-
Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report Mult. Scler. J. (IF 5.8) Pub Date : 2024-03-01 Raja Majid Afzal, Jeppe Romme Christensen, Rosa Maja Møhring Gynthersen, Anne-Mette Lebech, Morten Blinkenberg, Helene Mens
Objective:To describe a case of neoehrlichiosis, an emerging opportunistic tick-borne infection, in a patient with multiple sclerosis (MS) treated with ocrelizumab.Methods:This is a case study.Results:Our patient developed clinical infection over several months while on ocrelizumab and was ultimately diagnosed with neoehrlichiosis, caused by the bacteria Neoehrlichia mikurensis. Resolution of symptoms
-
Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-29 Timothy Reynold U Lim, Sunitha P Kumaran, Suradech Suthiphosuwan, Adrian I Espiritu, Ashley Jones, Amy Wei Lin, Jiwon Oh, Aditya Bharatha
Background:Performing routine brain magnetic resonance imaging (MRI) is widely accepted as the standard of care for disease monitoring in multiple sclerosis (MS), but the utility of performing routine spinal cord (SC) MRI for this purpose is still debatable.Objective:This study aimed to measure the frequency of new isolated cervical spinal cord lesions (CSLs) in people with MS (pwMS) undergoing routine
-
Reply: Mobile health interventions in multiple sclerosis: A systematic review Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-29 Christoph Heesen, Dagmar Lühmann
-
BCG vaccination and multiple sclerosis risk: A Norwegian cohort study Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-28 Ola Nakken, Jan Harald Aarseth, Stig Wergeland, Hein Stigum, Haakon E Meyer, Trygve Holmøy
Introduction:Bacillus Calmette–Guérin (BCG) vaccination induces long-lasting effects on the adaptive and innate immune systems and prevents development of experimental autoimmune encephalomyelitis and possibly also inflammatory disease activity in multiple sclerosis (MS).Objective:The objective is to examine if BCG given in early adulthood decreases MS risk.Methods:From 791,369 (52% females) Norwegians
-
Dissemination in time as a requirement for diagnosis of multiple sclerosis: Time for a change? Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-27 Aaron E Miller
The requirement to demonstrate dissemination in time (DIT) in order to diagnose multiple sclerosis (MS) has been enshrined in the literature since earliest efforts to establish diagnostic critera. However, various diagnostic criteria over the years, including the 2017 McDonald criteria, have inconsistently utilized this concept. This Viewpoint contends that current criteria for DIT are inadequate and
-
The impact of social distancing measures on anti–JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-26 Stephen C Krieger, Susie Sinks, Furong Huang, Julie Steverson, Tamar J Kalina, Kurt White, Robin L Avila
Background:The coronavirus disease 2019 (COVID-19) pandemic offered an epidemiological opportunity to evaluate if isolation and masking affected John Cunningham (JC) virus transmission.Objective:This study aimed to assess the proportion of natalizumab-treated patients who converted to a positive anti-JCV antibody serostatus before and during the pandemic.Methods:Data from TYSABRI Outreach: Unified
-
T1/T2-weighted ratio: A feasible MRI biomarker in multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-23 Mateus Boaventura, Jaume Sastre-Garriga, Carolina de Medeiros Rimkus, Àlex Rovira, Deborah Pareto
T1/T2-weighted ratio is a novel magnetic resonance imaging (MRI) biomarker based on conventional sequences, related to microstructural integrity and with increasing use in multiple sclerosis (MS) research. Different from other advanced MRI techniques, this method has the advantage of being based on routinely acquired MRI sequences, a feature that enables analysis of retrospective cohorts with considerable
-
Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-22 Callanan Emma, Petkova Vesela, Polly Kay, Huseyin Huseyin, Hassett Alison, Sittampalam Mara, De Angelis Floriana, Collorone Sara
We present a case of a 30-year-old man with relapsing-remitting multiple sclerosis who developed psoriasiform dermatitis following his second course of ocrelizumab. This resolved with topical therapies and discontinuation of treatment. Cases of psoriasiform rashes have been increasingly reported in the use of ocrelizumab and are possibly due to B-cell (CD20) depletion and T-cell overregulation. Nevertheless
-
Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-22 Steffen Pfeuffer
-
Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-22 Merve Bahar Ercan, Belgin Kocer, Taylan Altiparmak, Ilker Arslan
-
A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-20 Kian Jalaleddini, Robert A Bermel, Bari Talente, David Weinstein, Ferhan Qureshi, Maital Rasmussen, Sreeranjani Menon, Miyuru Amarapala, Kesshi Jordan, Ati Ghoreyshi, Shannon McCurdy, Mike Edgeworth
Objectives:We evaluate the potential clinical and cost impacts of discontinuing disease-modifying therapy (DMT) in people with multiple sclerosis (PwMS) when age-related immunosenescence can reduce DMT efficacy while increasing associated risks.Methods:A Markov model simulated clinical and cost impacts to the patient and payers when a proportion of eligible patients with relapsing remitting multiple
-
2.5-Year changes of connectivity dynamism are relevant for physical and cognitive deterioration in multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-19 Maria A Rocca, Giulia D’Amore, Paola Valsasina, Nicolò Tedone, Alessandro Meani, Massimo Filippi
Background:In MS, functional connectivity (FC) dynamism may influence disease evolution.Objectives:The objective is to assess time-varying functional connectivity (TVFC) changes over time at 2.5-year follow-up in MS patients according to physical and cognitive worsening.Methods:We collected 3T magnetic resonance imaging (MRI) for TVFC assessment (performed using sliding-window analysis of centrality)
-
Eye movement desensitization and reprocessing for depressed individuals with multiple sclerosis: A pilot study Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-19 Marco Rovaris, Elena Toselli, Laura Mendozzi, Sonia Di Tella, Alice Pirastru, Valeria Blasi, Francesca Baglio, Luca Ostacoli, Alessandra D’Abramo, Alessia Incerti, Isabel Fernandez, Francesco Pagnini, Cesare Cavalera
Background:Multiple studies have highlighted elevated rates of depression among individuals with Multiple Sclerosis (MS), with its associated symptoms posing a significant threat to overall well-being. Moreover, existing literature suggests a potential interconnection between depressive manifestations and the decline of physical functionalities in the context of MS.Objective:to examine the viability
-
What contributes to disability in progressive MS? A brain and cervical cord–matched quantitative MRI study Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-19 Carmen Tur, Marco Battiston, Marios C Yiannakas, Sara Collorone, Alberto Calvi, Ferran Prados, Baris Kanber, Francesco Grussu, Antonio Ricciardi, Patrizia Pajak, Daniele Martinelli, Torben Schneider, Olga Ciccarelli, Rebecca S Samson, Claudia AM Gandini Wheeler-Kingshott
Background:We assessed the ability of a brain-and-cord-matched quantitative magnetic resonance imaging (qMRI) protocol to differentiate patients with progressive multiple sclerosis (PMS) from controls, in terms of normal-appearing (NA) tissue abnormalities, and explain disability.Methods:A total of 27 patients and 16 controls were assessed on the Expanded Disability Status Scale (EDSS), 25-foot timed
-
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-17 Jack A Reeves, Maryam Mohebbi, Taylor Wicks, Fahad Salman, Alexander Bartnik, Dejan Jakimovski, Niels Bergsland, Ferdinand Schweser, Bianca Weinstock-Guttman, Michael G Dwyer, Robert Zivadinov
Background:Paramagnetic rim lesions (PRLs) have been linked to higher clinical disease severity and relapse frequency. However, it remains unclear whether PRLs predict future, long-term disease progression.Objectives:The study aimed to assess whether baseline PRLs were associated with subsequent long-term (10 years) Expanded Disability Status Scale (EDSS) increase and relapse frequency and, if so,
-
A custom-built step exergame training programme to prevent falls in people with multiple sclerosis: A multicentre randomised controlled trial Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-16 Phu Hoang, Daina L Sturnieks, Anna Butler, Carly Chaplin, Cameron Hicks, Joanne Lo, Mayna Ratanapongleka, Sophie Robinson, Natassia Smith, Jessica Turner, Arun V Krishnan, Michael Barnett, Simon Gandevia, Stephen R Lord, Jasmine C Menant
Background:Cognitive-motor step training can improve stepping, balance and mobility in people with multiple sclerosis (MS), but effectiveness in preventing falls has not been demonstrated.Objectives:This multisite randomised controlled trial aimed to determine whether 6 months of home-based step exergame training could reduce falls and improve associated risk factors compared with usual care in people
-
Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-15 Nicolas Collongues, Françoise Durand-Dubief, Christine Lebrun-Frenay, Bertrand Audoin, Xavier Ayrignac, Caroline Bensa, Kévin Bigaut, Bertrand Bourre, Clarisse Carra-Dallière, Jonathan Ciron, Gilles Defer, Arnaud Kwiatkowski, Emmanuelle Leray, Elisabeth Maillart, Romain Marignier, Guillaume Mathey, Nathalie Morel, Eric Thouvenot, Hélène Zéphir, Julie Boucher, Clémence Boutière, Pierre Branger, Angélique
Background:Epidemiological data reveal that 45% of persons with multiple sclerosis (PwMS) in France are more than 50 years. This population more than 50 is more susceptible to cancer, and this risk may be increased by frequent use of immunosuppressive drugs. Consequently, concerns have arisen about the potential increased risk of cancer in PwMS and how patients should be screened and managed in terms
-
VISIBL-MS: A bilingual educational framework to increase awareness of early multiple sclerosis Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-15 Shivam Patel, Seamus Rafferty, Laura Aquino, Saloni Chadha, Richard Ginocchio, Brooke Cyr, Joshua Fedorko, Jaime Imitola
Background:Despite advancements in treatments of multiple sclerosis (MS), there is a lack of awareness of early MS symptoms, especially in students and the public, contributing to delays in diagnosis and treatment. This review aims to identify gaps in tools to increase awareness and to provide a bilingual framework to facilitate recognition of early MS symptoms.Methods:We performed a literature review
-
Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-12 Christopher Elnan Kvistad, Anne Kristine Lehmann, Silje Agnethe Stokke Kvistad, Trygve Holmøy, Åslaug Rudjord Lorentzen, Linn Hereide Trovik, Einar Klæboe Kristoffersen, Lars Bø, Øivind Torkildsen
Background:Autologous hematopoietic stem cell transplantation (HSCT) is a potent treatment option for patients with aggressive relapsing-remitting multiple sclerosis (RRMS).Objective:To evaluate long-term outcomes of HSCT in MS.Methods:National retrospective single-center observational study of patients with aggressive RRMS that underwent HSCT in Norway from January 2015 to January 2018. Criteria for
-
Drop-out, adherence, and compliance in randomized controlled trials of exercise training in multiple sclerosis: Short report Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-09 Robert W Motl, Daniel I Russell, Lara A Pilutti, Alexandra P Metse, Claudia H Marck, Bryan Chan, Peixuan Zheng, Yvonne C Learmonth
We documented reporting and rates of drop-out, adherence, and compliance from 40 randomized controlled trials (RCTs) included in our meta-analysis on safety of exercise training (ET) in MS. We adopted definitions and metrics of adherence and compliance provided by the MoXFo adherence group. Drop-out was reported in 100% of the RCTs and approximated 10% for intervention and control conditions. Adherence
-
Disentangling multiple sclerosis phenotypes through Mendelian disorders: A network approach Mult. Scler. J. (IF 5.8) Pub Date : 2024-02-09 Gianmarco Bellucci, Maria Chiara Buscarinu, Roberta Reniè, Virginia Rinaldi, Rachele Bigi, Rosella Mechelli, Silvia Romano, Marco Salvetti, Giovanni Ristori
Background:The increasing knowledge about multiple sclerosis (MS) pathophysiology has reinforced the need for an improved description of disease phenotypes, connected to disease biology. Growing evidence indicates that complex diseases constitute phenotypical and genetic continuums with “simple,” monogenic disorders, suggesting shared pathomechanisms.Objectives:The objective of this study was to depict